Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Thomas Flaig

Concepts (418)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Urinary Bladder Neoplasms
49
2026
259
11.700
Why?
Prostatic Neoplasms
39
2024
972
6.310
Why?
Antineoplastic Combined Chemotherapy Protocols
34
2026
1998
4.110
Why?
Carcinoma, Transitional Cell
15
2026
70
3.610
Why?
Prostatic Neoplasms, Castration-Resistant
19
2024
54
3.590
Why?
Antineoplastic Agents
30
2025
2219
3.420
Why?
Kidney Neoplasms
23
2023
419
3.410
Why?
Carcinoma, Renal Cell
18
2023
231
3.010
Why?
Neoadjuvant Therapy
13
2026
475
2.450
Why?
Androgen Antagonists
15
2024
91
2.370
Why?
Medical Oncology
6
2026
345
1.960
Why?
Cisplatin
16
2026
347
1.860
Why?
Prednisone
15
2024
229
1.820
Why?
Neoplasm Invasiveness
12
2026
504
1.590
Why?
Urologic Neoplasms
7
2026
31
1.510
Why?
Pyrroles
7
2017
222
1.490
Why?
Cystectomy
10
2026
46
1.280
Why?
Indoles
8
2019
511
1.260
Why?
Taxoids
8
2025
115
1.250
Why?
Neoplasm Metastasis
25
2025
693
1.230
Why?
Androstenes
6
2024
16
1.220
Why?
Abiraterone Acetate
9
2021
15
1.220
Why?
Urothelium
3
2016
33
1.190
Why?
Antibodies, Monoclonal, Humanized
11
2026
992
1.170
Why?
Neoplasm Staging
14
2024
1488
1.110
Why?
Phenylurea Compounds
6
2016
122
1.000
Why?
Adenocarcinoma
7
2020
927
0.990
Why?
Mitoxantrone
5
2018
14
0.990
Why?
Prostate-Specific Antigen
12
2024
162
0.980
Why?
Male
99
2026
73396
0.980
Why?
Humans
144
2026
146342
0.960
Why?
Antineoplastic Agents, Hormonal
8
2017
196
0.960
Why?
Aged
64
2026
26432
0.920
Why?
Niacinamide
5
2016
103
0.910
Why?
Orchiectomy
4
2014
72
0.910
Why?
Mineralocorticoids
1
2024
7
0.860
Why?
Aged, 80 and over
31
2026
8391
0.820
Why?
Carcinoma, Small Cell
1
2024
172
0.820
Why?
Peripheral Nervous System Diseases
1
2025
135
0.800
Why?
Penile Neoplasms
1
2023
7
0.780
Why?
Phenylthiohydantoin
7
2024
44
0.780
Why?
Antibodies, Monoclonal
9
2026
1512
0.760
Why?
Carcinoma
2
2016
225
0.710
Why?
Testicular Neoplasms
3
2023
108
0.710
Why?
Middle Aged
54
2026
36619
0.690
Why?
ErbB Receptors
6
2018
636
0.680
Why?
Nitriles
11
2024
212
0.660
Why?
Chemotherapy, Adjuvant
10
2026
429
0.650
Why?
Treatment Outcome
29
2024
11821
0.630
Why?
Protein Kinase Inhibitors
6
2014
983
0.620
Why?
Immunotherapy
5
2022
671
0.620
Why?
Prognosis
14
2026
4351
0.590
Why?
Radiosurgery
4
2015
398
0.550
Why?
Deoxycytidine
6
2025
219
0.550
Why?
Disease-Free Survival
12
2017
778
0.540
Why?
Urinary Bladder
4
2026
194
0.540
Why?
Benzamides
8
2024
226
0.530
Why?
Bone Neoplasms
3
2015
272
0.530
Why?
Viscera
2
2014
17
0.530
Why?
Hematologic Diseases
2
2016
66
0.520
Why?
Sulfonamides
2
2012
594
0.520
Why?
Prostatectomy
5
2018
93
0.510
Why?
Erythrocytes, Abnormal
1
2016
14
0.490
Why?
Antineoplastic Agents, Immunological
2
2020
200
0.490
Why?
Practice Guidelines as Topic
3
2019
1591
0.470
Why?
Databases, Factual
5
2024
1493
0.460
Why?
Receptors, Androgen
2
2021
149
0.460
Why?
BCG Vaccine
3
2024
26
0.450
Why?
Pancreatitis
1
2016
146
0.440
Why?
Silymarin
4
2013
147
0.440
Why?
Genomics
2
2018
853
0.420
Why?
Doxorubicin
3
2026
416
0.420
Why?
Retrospective Studies
16
2024
17438
0.420
Why?
Leydig Cell Tumor
1
2014
8
0.410
Why?
Liver Neoplasms
3
2017
776
0.410
Why?
DNA Damage
3
2025
439
0.400
Why?
Epithelial-Mesenchymal Transition
2
2016
219
0.380
Why?
Proto-Oncogene Proteins p21(ras)
1
2013
250
0.360
Why?
Neoplasms
3
2025
2954
0.360
Why?
Hypothyroidism
1
2012
68
0.360
Why?
Organ Sparing Treatments
2
2025
37
0.350
Why?
United States
12
2026
16136
0.350
Why?
Multicenter Studies as Topic
2
2021
417
0.350
Why?
Administration, Intravesical
3
2022
15
0.350
Why?
Kaplan-Meier Estimate
9
2026
970
0.350
Why?
Therapies, Investigational
1
2011
18
0.350
Why?
Adult
30
2026
41087
0.350
Why?
Diethylstilbestrol
1
2011
4
0.350
Why?
Pyrazoles
3
2024
517
0.340
Why?
Gene Expression Profiling
1
2018
1792
0.340
Why?
Neoplasms, Germ Cell and Embryonal
2
2023
76
0.340
Why?
Angiomyolipoma
1
2011
21
0.340
Why?
Receptors, Vascular Endothelial Growth Factor
2
2013
109
0.340
Why?
Female
36
2026
79499
0.330
Why?
Sarcoma
1
2013
209
0.330
Why?
Neoplastic Cells, Circulating
1
2011
81
0.320
Why?
Leukemia, Myeloid, Acute
2
2008
702
0.310
Why?
Receptors, Fibroblast Growth Factor
1
2010
70
0.300
Why?
Disease Progression
10
2021
2867
0.300
Why?
Lung Neoplasms
5
2017
2675
0.300
Why?
Neoplasm Proteins
1
2013
444
0.300
Why?
Recombinant Fusion Proteins
1
2012
663
0.300
Why?
Molecular Targeted Therapy
1
2013
447
0.300
Why?
Androgen Receptor Antagonists
4
2024
35
0.300
Why?
Neoplasms, Multiple Primary
1
2010
57
0.300
Why?
Antineoplastic Agents, Phytogenic
2
2010
178
0.300
Why?
Tumor Suppressor Protein p53
1
2013
530
0.290
Why?
Lymphatic Diseases
1
2009
21
0.290
Why?
SEER Program
4
2023
233
0.290
Why?
Vascular Endothelial Growth Factors
1
2009
77
0.290
Why?
Vascular Endothelial Growth Factor A
2
2019
545
0.290
Why?
Cystitis
1
2009
24
0.290
Why?
Antibiotics, Antineoplastic
2
2026
141
0.280
Why?
Androstadienes
3
2013
77
0.280
Why?
Neuroblastoma
1
2010
177
0.270
Why?
Muscles
3
2024
330
0.270
Why?
Pneumatosis Cystoides Intestinalis
1
2008
21
0.270
Why?
Survival Rate
9
2021
2092
0.270
Why?
Intestinal Perforation
1
2008
46
0.270
Why?
Xeroderma Pigmentosum Group D Protein
2
2024
6
0.270
Why?
Carcinoma, Squamous Cell
1
2013
628
0.260
Why?
Neoplasm Recurrence, Local
4
2022
1160
0.260
Why?
Double-Blind Method
12
2021
2070
0.260
Why?
Clinical Trials as Topic
5
2018
1064
0.250
Why?
Pyrimidines
1
2011
532
0.250
Why?
Precision Medicine
1
2011
462
0.250
Why?
Pharmacogenetics
2
2026
176
0.250
Why?
Cell Line, Tumor
8
2025
3545
0.250
Why?
Survival Analysis
6
2021
1378
0.250
Why?
Testosterone
3
2021
419
0.250
Why?
Tomography, X-Ray Computed
5
2024
2786
0.240
Why?
Combined Modality Therapy
9
2020
1271
0.240
Why?
Nanotubes
2
2018
46
0.240
Why?
Quinazolines
4
2019
267
0.240
Why?
Methotrexate
2
2025
234
0.240
Why?
Cardiotoxicity
1
2026
35
0.240
Why?
Biomarkers, Tumor
5
2024
1339
0.230
Why?
Pancreatic Neoplasms
1
2014
944
0.230
Why?
Anilides
5
2023
83
0.230
Why?
Carboplatin
1
2006
168
0.230
Why?
Neoplasm Grading
6
2018
313
0.230
Why?
Gold
2
2018
118
0.230
Why?
Thiohydantoins
2
2024
5
0.230
Why?
Skin Neoplasms
1
2013
806
0.230
Why?
Practice Patterns, Physicians'
3
2024
1408
0.220
Why?
Vinca Alkaloids
1
2025
6
0.220
Why?
Dendrimers
1
2025
21
0.220
Why?
Bridged-Ring Compounds
1
2025
31
0.220
Why?
Gonadotropin-Releasing Hormone
2
2020
215
0.220
Why?
Lymphatic Metastasis
2
2018
335
0.220
Why?
Fanconi Anemia Complementation Group C Protein
1
2024
1
0.210
Why?
Hypokalemia
1
2024
23
0.210
Why?
Recombinational DNA Repair
1
2024
19
0.210
Why?
Retinoblastoma Binding Proteins
1
2024
10
0.210
Why?
Hematuria
1
2024
11
0.210
Why?
Radiotherapy, Adjuvant
2
2018
222
0.210
Why?
Ataxia Telangiectasia Mutated Proteins
1
2024
69
0.210
Why?
Drug Carriers
1
2025
138
0.210
Why?
Nanostructures
1
2025
105
0.200
Why?
Vinblastine
1
2024
75
0.200
Why?
Drug Synergism
3
2011
354
0.200
Why?
Dexamethasone
1
2006
368
0.200
Why?
Drug Resistance, Neoplasm
3
2018
893
0.200
Why?
Tumor Microenvironment
3
2023
747
0.200
Why?
Societies, Medical
2
2018
907
0.200
Why?
Androstenols
3
2015
4
0.200
Why?
Randomized Controlled Trials as Topic
3
2021
1763
0.200
Why?
Dose-Response Relationship, Drug
5
2013
2022
0.190
Why?
Tosyl Compounds
4
2018
17
0.190
Why?
Drug Administration Schedule
4
2021
790
0.190
Why?
Steroid 17-alpha-Hydroxylase
2
2014
5
0.190
Why?
Lymph Node Excision
3
2026
174
0.190
Why?
Vitamin D
1
2006
402
0.190
Why?
Cell-Free Nucleic Acids
1
2023
40
0.180
Why?
Gene Expression Regulation, Neoplastic
2
2021
1432
0.180
Why?
Retroperitoneal Space
1
2021
19
0.180
Why?
Tissue Extracts
2
2012
19
0.170
Why?
Indazoles
2
2012
86
0.170
Why?
Kallikreins
2
2019
25
0.170
Why?
Retreatment
1
2021
79
0.160
Why?
Sleep Initiation and Maintenance Disorders
1
2024
198
0.160
Why?
Bone Marrow Transplantation
1
2002
301
0.160
Why?
Quality of Life
4
2024
3200
0.160
Why?
Genetic Heterogeneity
1
2020
67
0.150
Why?
Patient Reported Outcome Measures
2
2024
516
0.150
Why?
Phosphatidylcholines
2
2013
131
0.150
Why?
Time Factors
5
2020
7109
0.150
Why?
Yttrium
1
2018
5
0.140
Why?
Angiogenesis Inhibitors
2
2021
239
0.140
Why?
In Situ Hybridization, Fluorescence
2
2011
334
0.140
Why?
Euterpe
1
2018
4
0.140
Why?
Cell Adhesion Molecules
1
2020
180
0.140
Why?
Fluorides
1
2018
50
0.140
Why?
Apoptosis
1
2007
2439
0.140
Why?
Costimulatory and Inhibitory T-Cell Receptors
1
2018
7
0.140
Why?
Odds Ratio
1
2021
1077
0.130
Why?
Antioxidants
2
2013
544
0.130
Why?
Central Nervous System
1
2020
278
0.130
Why?
Piperidines
2
2010
225
0.130
Why?
Congresses as Topic
2
2012
226
0.130
Why?
Tumor Escape
1
2018
50
0.130
Why?
Genome-Wide Association Study
1
2025
1537
0.130
Why?
History, 21st Century
2
2015
224
0.130
Why?
Microscopy, Fluorescence
3
2018
404
0.130
Why?
Genome
1
2020
307
0.130
Why?
Cancer Vaccines
1
2019
161
0.130
Why?
Neoplasm, Residual
2
2021
143
0.130
Why?
Polymorphism, Single Nucleotide
1
2025
2240
0.130
Why?
Blotting, Western
2
2010
1177
0.130
Why?
Proton Therapy
1
2017
16
0.130
Why?
Biopsy
3
2018
1075
0.120
Why?
Goserelin
3
2018
8
0.120
Why?
Erythrocyte Indices
1
2016
33
0.120
Why?
Plant Extracts
1
2018
192
0.120
Why?
Aftercare
1
2018
225
0.120
Why?
Electronic Health Records
1
2025
1210
0.120
Why?
Fatal Outcome
2
2008
302
0.120
Why?
Oligopeptides
1
2018
264
0.120
Why?
Mutation
2
2024
4093
0.120
Why?
Dyslipidemias
1
2018
184
0.120
Why?
Genetic Predisposition to Disease
1
2025
2488
0.120
Why?
Adverse Drug Reaction Reporting Systems
1
2016
81
0.120
Why?
Watchful Waiting
1
2016
90
0.120
Why?
United States Food and Drug Administration
1
2016
208
0.110
Why?
Prostate
2
2021
159
0.110
Why?
High-Throughput Nucleotide Sequencing
1
2018
539
0.110
Why?
Magnetic Resonance Imaging
4
2024
3926
0.110
Why?
Disease Management
1
2019
651
0.110
Why?
Radiation Tolerance
1
2015
101
0.110
Why?
Cytochrome P-450 Enzyme Inhibitors
1
2014
13
0.100
Why?
Ablation Techniques
1
2014
36
0.100
Why?
Soft Tissue Neoplasms
1
2015
133
0.100
Why?
Mitotic Index
1
2014
24
0.100
Why?
Patient Selection
1
2018
728
0.100
Why?
Neoplasms, Hormone-Dependent
1
2014
33
0.100
Why?
Neoplasms, Complex and Mixed
1
2013
7
0.100
Why?
Glucocorticoids
1
2018
536
0.100
Why?
Insurance, Health
1
2016
318
0.100
Why?
beta-Galactosidase
1
2013
73
0.100
Why?
Carcinoma, Medullary
1
2013
16
0.100
Why?
Breeding
1
2013
64
0.100
Why?
Keratins
1
2013
57
0.100
Why?
Hyperthermia, Induced
1
2014
119
0.100
Why?
Interleukin-2
1
2014
434
0.100
Why?
Breast Neoplasms
1
2026
2418
0.100
Why?
Staining and Labeling
1
2013
148
0.090
Why?
Hyperplasia
1
2013
164
0.090
Why?
Urogenital Neoplasms
1
2012
5
0.090
Why?
Tumor Stem Cell Assay
1
2012
33
0.090
Why?
Sirolimus
2
2014
282
0.090
Why?
Geriatrics
1
2014
96
0.090
Why?
Organ Specificity
1
2013
307
0.090
Why?
Pyridines
2
2023
610
0.090
Why?
Integrases
1
2013
117
0.090
Why?
Fluorescent Antibody Technique
1
2013
345
0.090
Why?
Adenoviridae
1
2013
197
0.090
Why?
Bevacizumab
2
2025
169
0.090
Why?
Nephrectomy
2
2013
172
0.090
Why?
Cell Proliferation
2
2012
2502
0.090
Why?
Reproducibility of Results
2
2013
3416
0.090
Why?
Population Surveillance
1
2015
481
0.090
Why?
Nanoparticles
1
2018
523
0.090
Why?
Celecoxib
1
2012
41
0.090
Why?
Thyroid Hormones
1
2012
69
0.090
Why?
Bone Diseases
1
2012
60
0.090
Why?
RNA, Untranslated
1
2013
125
0.090
Why?
Thyroid Gland
1
2012
93
0.090
Why?
Quinolines
1
2013
191
0.090
Why?
Animals
6
2025
38107
0.090
Why?
Brain Neoplasms
1
2021
1325
0.080
Why?
Imidazoles
1
2012
245
0.080
Why?
Cross-Over Studies
3
2021
615
0.080
Why?
Denosumab
1
2010
10
0.080
Why?
RANK Ligand
1
2010
29
0.080
Why?
PubMed
1
2010
15
0.080
Why?
Reoperation
1
2014
645
0.080
Why?
Benzenesulfonates
1
2010
23
0.080
Why?
Erlotinib Hydrochloride
1
2010
71
0.080
Why?
Vimentin
1
2010
47
0.080
Why?
Insulin-Like Growth Factor Binding Protein 3
1
2010
32
0.080
Why?
Cell Separation
1
2011
300
0.080
Why?
Mesoderm
1
2010
147
0.070
Why?
Follow-Up Studies
3
2026
5439
0.070
Why?
Carcinoma, Hepatocellular
1
2013
370
0.070
Why?
Xenograft Model Antitumor Assays
1
2012
930
0.070
Why?
Tumor Cells, Cultured
1
2011
882
0.070
Why?
Hypertension
1
2018
1272
0.070
Why?
Mice
3
2025
18297
0.070
Why?
Carcinoma, Papillary
1
2009
83
0.070
Why?
Nephrolithiasis
1
2009
10
0.070
Why?
Gynecomastia
1
2008
6
0.070
Why?
Metaplasia
1
2009
54
0.070
Why?
Cadherins
1
2010
202
0.070
Why?
Risk
1
2011
920
0.070
Why?
Age Factors
1
2016
3347
0.070
Why?
Chromatography, Liquid
1
2010
453
0.070
Why?
Genotype
1
2013
1879
0.070
Why?
Cardiovascular Diseases
2
2018
2219
0.070
Why?
Mice, Transgenic
1
2013
2134
0.070
Why?
Drug Therapy, Combination
1
2011
1036
0.070
Why?
Southwestern United States
1
2008
93
0.070
Why?
Mediastinal Diseases
1
2007
10
0.070
Why?
Insulin-Like Growth Factor I
1
2010
320
0.070
Why?
Carcinoid Tumor
1
2007
21
0.070
Why?
Proportional Hazards Models
3
2016
1331
0.060
Why?
Liver Failure, Acute
1
2008
78
0.060
Why?
Hormone Replacement Therapy
1
2008
107
0.060
Why?
Risk Factors
5
2018
10921
0.060
Why?
Tandem Mass Spectrometry
1
2010
576
0.060
Why?
Glucuronides
1
2006
18
0.060
Why?
Neoplasms, Second Primary
1
2008
103
0.060
Why?
Medical History Taking
1
2007
117
0.060
Why?
Spectrophotometry, Ultraviolet
1
2006
82
0.060
Why?
Excipients
1
2006
55
0.060
Why?
Liver Function Tests
1
2006
103
0.060
Why?
Chemistry, Pharmaceutical
1
2006
116
0.060
Why?
Zimbabwe
1
2026
76
0.060
Why?
Syndrome
1
2007
380
0.060
Why?
Spectrometry, Mass, Electrospray Ionization
1
2006
175
0.060
Why?
Young Adult
5
2024
14330
0.060
Why?
Pedigree
1
2007
512
0.060
Why?
Radiography
1
2008
861
0.060
Why?
Sarcoidosis
1
2007
164
0.060
Why?
Everolimus
2
2017
112
0.060
Why?
Drug Liberation
1
2025
36
0.060
Why?
Forecasting
1
2007
388
0.050
Why?
Chitosan
1
2025
39
0.050
Why?
Metabolic Syndrome
1
2008
364
0.050
Why?
Signal Transduction
2
2016
5246
0.050
Why?
Diagnosis, Differential
1
2009
1503
0.050
Why?
BRCA2 Protein
1
2024
69
0.050
Why?
BRCA1 Protein
1
2024
84
0.050
Why?
Gastrointestinal Diseases
1
2006
220
0.050
Why?
Melanoma
1
2011
765
0.050
Why?
Cystoscopy
1
2024
21
0.050
Why?
Epithelial Cells
1
2010
1119
0.050
Why?
Radiotherapy
2
2015
209
0.050
Why?
Ultrasonography
2
2024
788
0.050
Why?
Biomarkers
2
2023
4340
0.050
Why?
Echocardiography
1
2026
645
0.050
Why?
Immunohistochemistry
2
2020
1712
0.050
Why?
Quinoxalines
1
2023
65
0.050
Why?
Carcinoma, Non-Small-Cell Lung
1
2012
1195
0.050
Why?
Incidence
2
2026
2936
0.050
Why?
Ubiquitin-Protein Ligases
1
2024
198
0.050
Why?
Referral and Consultation
1
2009
881
0.040
Why?
Maximum Tolerated Dose
2
2013
217
0.040
Why?
Prospective Studies
2
2026
8123
0.040
Why?
Steroid Synthesis Inhibitors
1
2021
1
0.040
Why?
Disease Models, Animal
1
2012
4580
0.040
Why?
Immune System Diseases
1
2002
43
0.040
Why?
Policy
1
2022
147
0.040
Why?
Prednisolone
1
2021
65
0.040
Why?
Clinical Trials, Phase III as Topic
1
2021
116
0.040
Why?
Metabolic Diseases
1
2002
114
0.040
Why?
Health Care Costs
1
2024
423
0.040
Why?
Phosphatidylinositol 3-Kinases
1
2022
384
0.040
Why?
Asymptomatic Diseases
1
2021
102
0.040
Why?
Tumor Burden
1
2021
326
0.040
Why?
Proto-Oncogene Proteins c-akt
1
2022
441
0.040
Why?
Nectins
1
2020
7
0.040
Why?
Proteomics
1
2007
1203
0.040
Why?
Neovascularization, Pathologic
1
2021
287
0.040
Why?
Mass Screening
1
2008
1307
0.040
Why?
TOR Serine-Threonine Kinases
1
2022
455
0.040
Why?
Ytterbium
1
2018
2
0.040
Why?
HLA-A2 Antigen
1
2019
36
0.040
Why?
Erbium
1
2018
4
0.040
Why?
Drug-Related Side Effects and Adverse Reactions
1
2021
266
0.040
Why?
Hospitals
1
2023
738
0.040
Why?
Estrogen Receptor alpha
1
2020
154
0.030
Why?
Luminescent Measurements
1
2018
75
0.030
Why?
Fruit and Vegetable Juices
1
2018
23
0.030
Why?
Lasers
1
2018
127
0.030
Why?
Risk Assessment
1
2008
3712
0.030
Why?
Pain
1
2024
790
0.030
Why?
Hydrogels
1
2025
708
0.030
Why?
Granulocyte-Macrophage Colony-Stimulating Factor
1
2019
158
0.030
Why?
DNA Methylation
1
2023
725
0.030
Why?
National Cancer Institute (U.S.)
1
2017
56
0.030
Why?
Laparoscopy
1
2021
487
0.030
Why?
Antibodies
1
2018
400
0.030
Why?
DNA
1
2023
1421
0.030
Why?
Risk Reduction Behavior
1
2018
220
0.030
Why?
Molecular Diagnostic Techniques
1
2016
104
0.030
Why?
Thoracic Neoplasms
1
2015
40
0.030
Why?
Abdominal Neoplasms
1
2015
48
0.030
Why?
Placebos
1
2015
192
0.030
Why?
Spectrophotometry, Atomic
1
2014
13
0.030
Why?
Nanoconjugates
1
2014
2
0.030
Why?
Radiotherapy Planning, Computer-Assisted
1
2015
150
0.030
Why?
Administration, Oral
1
2017
872
0.030
Why?
Radiotherapy, Intensity-Modulated
1
2015
143
0.030
Why?
Smoking Cessation
1
2018
442
0.030
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
2018
449
0.030
Why?
Platelet Aggregation Inhibitors
1
2018
499
0.030
Why?
Antihypertensive Agents
1
2018
519
0.030
Why?
Benchmarking
1
2015
193
0.020
Why?
Lipids
1
2018
714
0.020
Why?
Cell Death
1
2014
379
0.020
Why?
Accidental Falls
1
2015
227
0.020
Why?
Hydroxamic Acids
1
2012
96
0.020
Why?
Blood Pressure
1
2018
1765
0.020
Why?
Dose-Response Relationship, Radiation
1
2011
141
0.020
Why?
Health Policy
1
2014
399
0.020
Why?
Histone Deacetylase Inhibitors
1
2012
219
0.020
Why?
Androgens
1
2011
179
0.020
Why?
Polyethylene Glycols
1
2014
650
0.020
Why?
Multivariate Analysis
1
2012
1543
0.020
Why?
Fatigue
1
2011
363
0.020
Why?
Sex Factors
1
2014
2107
0.020
Why?
Seizures
1
2012
489
0.020
Why?
Positron-Emission Tomography
1
2009
343
0.020
Why?
Radionuclide Imaging
1
2007
116
0.020
Why?
Cell Membrane Permeability
1
2006
88
0.020
Why?
Adolescent
1
2024
22557
0.010
Why?
Cell Survival
1
2006
1105
0.010
Why?
Head and Neck Neoplasms
1
2008
563
0.010
Why?
Flaig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)